PART I. FINANCIAL INFORMATION [Note About Forward-Looking Statements](index=3&type=section&id=Note%20About%20Forward%20Looking%20Statements) The report includes forward-looking statements subject to risks like supply chain disruptions and economic volatility - The report identifies several key risks that could cause actual results to differ from forward-looking statements[9](index=9&type=chunk)[10](index=10&type=chunk)[15](index=15&type=chunk) - Key risks include **supply chain interruptions**, global market volatility, foreign exchange fluctuations, and regulatory compliance failures[10](index=10&type=chunk)[15](index=15&type=chunk) [Item 1. Condensed Consolidated Financial Statements](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) The unaudited financial statements show results for the three and nine months ended September 30, 2022 [Condensed Consolidated Statements of Income (Loss)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20(Loss)) The company reported a Q3 2022 net loss of $107.3 million, driven by a significant goodwill impairment charge Condensed Consolidated Statements of Income (Loss) (in thousands) | Metric | Q3 2022 | Q3 2021 | YTD 2022 | YTD 2021 | | :--- | :--- | :--- | :--- | :--- | | **Net Revenue** | **$252,605** | **$253,215** | **$746,931** | **$765,301** | | Gross Profit | $170,918 | $168,664 | $523,711 | $504,351 | | Impairment of goodwill | $129,396 | $— | $129,396 | $— | | Operating (Loss) Income | $(131,973) | $16,422 | $(90,712) | $(25,538) | | **Net Loss** | **$(107,344)** | **$(43,443)** | **$(87,907)** | **$(130,691)** | | Diluted Loss Per Share | $(2.01) | $(0.84) | $(1.64) | $(2.63) | [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets remained flat at $2.21 billion, with a notable goodwill decrease and liability increase Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $231,114 | $207,992 | | Restricted cash | $275,165 | $— | | Goodwill | $742,370 | $899,525 | | **Total Assets** | **$2,212,878** | **$2,200,951** | | Current debt obligations | $21,695 | $229,673 | | Long-term debt obligations | $518,249 | $9,849 | | **Total Liabilities** | **$1,065,915** | **$906,306** | | **Total Stockholders' Equity** | **$1,146,963** | **$1,294,645** | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow decreased while financing cash flow increased due to new debt proceeds Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by operating activities | $51,218 | $69,064 | | Net cash (used in) provided by investing activities | $(27,461) | $40,535 | | Net cash provided by (used in) financing activities | $281,787 | $(178,183) | | **Net increase (decrease) in cash, cash equivalents and restricted cash** | **$298,287** | **$(70,986)** | [Notes to the Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Key notes cover the ALung acquisition, a $129.4 million goodwill impairment, new financing, and major litigation updates - The company acquired the remaining 97% of ALung Technologies for up to **$110.0 million**, including contingent consideration[39](index=39&type=chunk) - A goodwill impairment charge of **$129.4 million** was recognized for the Advanced Circulatory Support (ACS) reporting unit[54](index=54&type=chunk) - The company entered into new term loan facilities for an aggregate principal amount of **$350 million**[75](index=75&type=chunk)[76](index=76&type=chunk) - In the SNIA environmental litigation, the company has appealed a decision ordering it to pay approximately **€453.6 million**[121](index=121&type=chunk)[122](index=122&type=chunk) - An additional liability of **$18.6 million** was recorded in Q3 2022 for the 3T device product liability litigation[116](index=116&type=chunk)[117](index=117&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses segment performance amidst global disruptions, a goodwill impairment, and new debt financing [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Q3 2022 revenue was flat as Neuromodulation growth was offset by declines in other segments and a large impairment Net Revenue by Segment (in thousands) | Segment | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Cardiopulmonary | $120,959 | $123,235 | (1.8)% | | Neuromodulation | $121,835 | $113,287 | 7.5% | | Advanced Circulatory Support | $8,636 | $15,399 | (43.9)% | | **Total** | **$252,605** | **$253,215** | **(0.2)%** | - The ACS segment recorded a goodwill impairment of **$129.4 million** in Q3 2022, driven by a **29% year-to-date revenue decline**[199](index=199&type=chunk) - Neuromodulation segment income increased due to higher revenue and a favorable change in contingent consideration fair value[188](index=188&type=chunk) - Cardiopulmonary segment income decreased due to a **$20.1 million increase** in litigation provisions and legal costs[185](index=185&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity was impacted by securing a €270.0 million bank guarantee for litigation, funded by new term loans - To suspend payment of damages in the SNIA litigation, the company provided a **€270.0 million bank guarantee**, collateralized by **$275.2 million** in restricted cash[216](index=216&type=chunk)[218](index=218&type=chunk) - A **$220.0 million Bridge Loan Facility** was used to post collateral and was later repaid using proceeds from a new **$350 million Term Facility**[217](index=217&type=chunk)[221](index=221&type=chunk) Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Operating activities | $51,218 | $69,064 | | Investing activities | $(27,461) | $40,535 | | Financing activities | $281,787 | $(178,183) | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=46&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from foreign currency, equity prices, and interest rates - The company's primary market risks stem from **foreign currency exchange rates**, equity price fluctuations, and interest rate changes[227](index=227&type=chunk) [Item 4. Controls and Procedures](index=46&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of the end of the quarter[228](index=228&type=chunk) - **No material changes** in internal control over financial reporting occurred during the quarter ended September 30, 2022[229](index=229&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=47&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 10 for details on material pending legal and regulatory proceedings - For information on material legal proceedings, the report refers to **"Note 10. Commitments and Contingencies"** in the financial statements[231](index=231&type=chunk) [Item 1A. Risk Factors](index=47&type=section&id=Item%201A.%20Risk%20Factors) Updated risks include heightened supply chain disruptions, ongoing FDA regulatory issues, and international business uncertainties - **Supply chain risks** are exacerbated by COVID-19, leading to delays, labor shortages, and inflationary pressures[235](index=235&type=chunk) - The company faces ongoing **FDA regulatory risk**, highlighted by a 2015 Warning Letter and a recent Form 483[236](index=236&type=chunk)[237](index=237&type=chunk) - Increased EPA scrutiny on **ethylene oxide (EtO) emissions** presents a potential risk to product sterilization processes[242](index=242&type=chunk) - International operations carry significant risks, including impacts from the **Russia-Ukraine conflict** and currency fluctuations[243](index=243&type=chunk)[246](index=246&type=chunk) [Item 5. Other Information](index=49&type=section&id=Item%205.%20Other%20Information) Disclosures include business dealings in Iran and the planned retirement of the General Counsel - The company disclosed sales to distributors in Iran, generating net revenue of **$1.5 million** for the three months ended September 30, 2022[251](index=251&type=chunk)[253](index=253&type=chunk) - Keyna Skeffington, General Counsel and Company Secretary, will **retire** from the company on June 30, 2023[254](index=254&type=chunk) [Item 6. Exhibits](index=51&type=section&id=Item%206.%20Exhibits) This section lists filed exhibits, including CEO/CFO certifications and Interactive Data Files - The exhibits filed with this report include **CEO and CFO certifications** (Exhibits 31.1, 31.2, 32.1) and Interactive Data Files (Exhibit 101)[256](index=256&type=chunk)

Financial Data and Key Metrics Changes - Revenue for Q2 2022 was $254 million, representing a 7% increase year-over-year, excluding heart valves [15][18] - Adjusted gross margin was 69%, consistent with Q2 2021, while adjusted operating income decreased to $33 million from $38 million in the prior year [15][16] - Adjusted diluted earnings per share increased to $0.53 from $0.50 in Q2 2021 [16] - Cash balance at June 30 was $407 million, up from $208 million at year-end 2021, while total debt increased to $466 million from $240 million [17] Segment Results and Key Metrics Changes - Cardiopulmonary segment revenue was $126 million, a 14% increase year-over-year, driven by mid-teen growth in oxygenator and heart-lung machine sales [6][10] - Epilepsy revenue increased by 3%, with growth in Europe and the rest of the world, while US revenue was flat year-over-year [7][8] - ACS revenue was $9 million, down 29% year-over-year, primarily due to a decline in severe COVID cases [9][10] Market Data and Key Metrics Changes - The rest of the world region for epilepsy revenue achieved 19% growth, led by Brazil, Japan, and Taiwan [8] - US epilepsy results were impacted by hospital staffing challenges and COVID-related postponements, with total implants down in the mid-single digits [8] Company Strategy and Development Direction - The company aims to drive long-term shareholder value through a strategic triangle underpinned by the LivaNova business system [20] - The focus remains on expanding the sales force and enhancing commercial execution in key markets [8][10] Management's Comments on Operating Environment and Future Outlook - Management noted that the second quarter performance reflects the strength of the diverse portfolio despite macroeconomic challenges [20] - The updated full-year outlook anticipates constant currency revenue growth of 4% to 6%, with adjusted EPS guidance of $2.25 to $2.45 [18][20] Other Important Information - The heart valve business was divested on June 1, 2021, impacting year-over-year comparisons [10] - The company is progressing with the RECOVER study and anticipates a transition to a prospective longitudinal study in late 2022 or early 2023 [12] Q&A Session Summary Question: What gives confidence that ACS will return to growth in the second half? - Management indicated that improvements in staffing and the expansion of the sales force are expected to drive growth in ACS [23] Question: Update on RECOVER study enrollment? - Management confirmed that reaching 350 patients is imminent, with results expected by the end of the month [24] Question: Is the interest cost from the new term loan included in adjusted EPS? - Management confirmed that the interest cost from the term loan is treated as an extraordinary item and excluded from adjusted EPS [25] Question: Update on CMS response timing for RECOVER? - Management stated that the transition to registry is expected late this year or early next year, with a detailed timeline for data submission to CMS [29][31] Question: How does the company view the impact of inflation and currency on guidance? - Management indicated that both inflation and currency are significant factors impacting guidance, with expectations of a $0.30 reduction at the midpoint [36][37] Question: Update on heart-lung machine product launch? - Management expects a limited commercial release by the end of the year, with full release early in Q1 2023 [38] Question: How many patients will have treatment close to 12 months by the end of the month for RECOVER? - Management did not provide specific numbers but indicated that separation in treatment effects is expected to be observed as patients approach the one-year mark [60]

| --- | --- | --- | --- | |----------------------------|-------|-------|-------| | | | | | | Ethan, VNS Therapy Patient | | | | Second Quarter 2022 Earnings Presentation August 3, 2022 Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its char ...

LivaNova PLC (NASDAQ:LIVN) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Mike Polark - Wolfe Research Mike Matson - Needham & Company, LLC Adam Maeder - Piper Sandler Philip Coover - Goldman Sachs Zachary Weiner - Jefferies LLC Operator Good day, ladies and gentlemen, ...

Liva:Nova First Quarter 2022 Earnings Performance May 4, 2022 Michael, VNS Therapy Patient, DTD Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, LivaNova's plans, objectives, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC Indicate by check mark whether the registrant has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 20 Eastbourne Terrace, London, United Kingdom, W2 6LG (Address of principal executive of ices) ....................... (Zip Code) Registrant's telephone number, including area code: (44) (0) 203 325-0660 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trad ...

Call Start: 08:00 January 1, 0000 8:40 AM ET LivaNova PLC (NASDAQ:LIVN) Q4 2021 Earnings Conference Call February 23, 2022, 8:00 AM ET Company Participants Damien McDonald – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Matthew Dodds – Senior Vice President of Corporate Development Conference Call Participants Adam Maeder – Piper Sandler Rick Wise – Stifel Mike Matson – Needham & Company Amit Hazan – Goldman Sachs Zach Tuckwell – Jefferies Matthew Taylor – Union Bank of Switzerland Oper ...

Liva Nova Health innovation that matters 4Q and Full-Year 2021 Earnings Performance February 23, 2022 Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, LivaNova's plans, objectives, s ...